

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Thiamine and folic acid in the treatment of cognitive impairment in maintenance hemodialysis patients: A prospective, randomized, placebo-controlled, double-blind, multi-center study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050605
Article Type:	Protocol
Date Submitted by the Author:	26-Feb-2021
Complete List of Authors:	<p>Lu, Renhua; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Gu, Le-yi; Shanghai Jiao Tong University, Department of Nephrology; Shanghai Jiao Tong University, Department of Nephrology Zhang, Weiming; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Guo, Yongping; Shanghai Sixth Peoples Hospital, Department of Nephrology Zang, Xiujuan; Shanghai Songjiang District Central Hospital, Department of Nephrology Zhou, Yan; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Radiology Yu, Ling; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Neurology Pan, Shuting; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Clinical Center for Investigation Pang, Huihua; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Liu, Shang; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Xie, Kewei; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Li, Ping; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Zeng, Xiaojun; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Lu, Yifei; Shanghai University of Traditional Chinese Medicine, Department of pharmacy</p>
Keywords:	End stage renal failure < NEPHROLOGY, Delirium & cognitive disorders < PSYCHIATRY, Clinical trials < THERAPEUTICS



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Thiamine and folic acid in the treatment of cognitive impairment in**
5
6 **maintenance hemodialysis patients: A prospective, randomized,**
7
8 **placebo-controlled, double-blind, multi-center study**
9
10

11
12 **Renhua Lu¹, Leyi Gu^{1,2*}, Weiming Zhang¹, Yongping Guo³, Xiujuan Zang⁴, Yan Zhou⁵,**
13
14 **Ling Yu⁶, Shuting Pan², Huihua Pang¹, Shang Liu¹, Kewei Xie¹, Ping Li¹, Xiaojun Zeng¹,**
15
16 **Yifei Lu⁷**

17
18
19
20
21
22 1 Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
23
24 Shanghai, China

25
26 2 Clinical Center for Investigation, Renji Hospital, School of Medicine, Shanghai Jiao Tong
27
28 University, Shanghai, China

29
30 3 Department of Nephrology, East branch of Shanghai Sixth People's Hospital, Shanghai, China

31
32 4 Department of Nephrology, Shanghai Songjiang District Central Hospital, Shanghai, China

33
34 5 Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
35
36 Shanghai, China

37
38 6 Department of Neurology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
39
40 Shanghai, China

41
42 7 Department of pharmacy, Shanghai University of Traditional Chinese Medicine

43
44 *Correspondence: Leyi Gu, Department of Nephrology, Renji Hospital, 160 Pujian Road,
45
46 Shanghai, China. E-Mail guleyi@aliyun.com

47
48
49
50
51
52
53
54
55
56 **ABSTRACT**

57
58
59 **Introduction**
60

Cognitive impairment (CI) is the common complications in maintenance hemodialysis (MHD) patients. Recently, the pathogenesis of CI has been discussed and oxidative stress is one of the main mechanisms in these patients. Thiamine and folic acid, which play an important role in relieving the production of reactive oxygen species, reducing homocysteine levels, improving oxidative stress in the nervous system. In pilot study, cognitive function was significantly improved in the group with thiamine and folic supplementation. Based on this result, we hypothesize that thiamine combined with folic acid supplementation may improve cognitive function in patients with MHD.

Methods and analysis In this prospective, randomized, placebo-controlled, double-blind, multi-center study, we enrolled patients undergoing hemodialysis who had the Montreal Cognitive Assessment (MoCA) score lower than 26 to treatment group (thiamine 90mg/day combined with folic acid 30mg/day) or control group (thiamine placebo 90mg/day combined with folic acid placebo 30mg/day). All subjects were followed up for 96 weeks. The primary endpoint is the comparison of ADAS-Cog score between the treatment group and the control group at 96 weeks of follow-up. The secondary endpoints included serum thiamine, folate, homocysteine levels, cranial functional magnetic resonance imaging, and prognosis. The central randomization method will be adopted in this study and the principles of placebo-controlled, double-blind randomized control will be followed. The comparisons among ADAS-Cog scores and other secondary endpoints over time within subjects was conducted by using repeated measure ANOVA, and pairwise t-test with Bonferroni adjustment was performed for multiple comparisons. On the other hand, for comparisons between treatment and control group, simple one-way ANOVA or Wilcoxon rank sum test was used. The chisquare method was used for statistical analysis of the categorical data. Kaplan-Meier survival curve was used for survival analysis. A $p < 0.05$ was considered statistically significant difference. Statistical analyses were conducted with SPSS.

Keywords: End-stage renal disease; Cognitive function; Vitamins B; Double-blind; Multi-center

Ethics and dissemination This trial has been approved by Shanghai Jiao Tong University School of Medicine, Renji Hospital Ethics Committee (KY2019-199). After publication of study results, trial report will be published in peer-reviewed journals and/or in national or international conferences.

1
2
3
4 **Trial registration number** ChiCTR2000029297
5

6 **Strengths and limitations of this study**
7

- 8
9
10 ● This is a prospective, randomized, placebo-controlled, double-blind, multi-center study in
11 maintenance hemodialysis patients addressing the complication of cognitive impairment.
12
13
14 ● The trial includes treatment and control group.
15
16
17 ● It provides important 96 weeks data on cognitive function, serum thiamine, folate,
18 homocysteine levels, cranial functional magnetic resonance imaging, and mortality.
19
20
21 ● Laboratory test and adverse events were closely monitored to ensure the safety of the study
22 during follow-up.
23
24
25
26
27
28

29 **INTRODUCTION**
30

31
32 This publication describes the study design and protocol of a clinical trial on
33 thiamine and folic acid in the treatment of cognitive impairment in maintenance
34 hemodialysis patients: A prospective, randomized, placebo-controlled, double-blind,
35 multi-center study (Version 2.0; Date 08 May, 2020).
36
37
38
39

40 **Background**
41

42
43 Cognitive impairment (CI) is one of the common neurological complications in
44 patients with end stage renal disease (ESRD)^[1]. Our previous single-center cohort
45 observational study showed that the incidence of CI in patients with maintenance
46 hemodialysis (MHD) was 51.6%^[2].
47
48
49
50

51
52 As we know, acute neurological complications such as stroke which is taken
53 seriously concern by nephrologist. However, cognitive impairment may be ignored in
54 patients on MHD by nephrologist. At the same time, because of the dormant clinical
55 symptoms in early cognitive impairment patients, this complication can not be timely
56 diagnosed and treated, significantly reduce the patient's quality of life, and leads to the
57
58
59
60

1
2
3
4 poor clinical prognosis. These bring to the country's social and family burden which
5 need to cause the extensive concern of the medical profession.
6
7

8
9 In our single-center randomized controlled pilot study, 50 MHD patients with
10 cognitive impairment were enrolled, including the treatment group (n=25, Thiamine
11 90mg/day combined with folic acid 30mg/day) and the control group (n=25,
12 nonintervention). After 2 years of follow-up, cognitive function was significantly
13 improved in the treatment group. The 2-year survival rate was also found to be better
14 in the treatment group than in the control group. In addition, there was no statistically
15 significant difference in safety between two groups.
16
17
18
19
20
21
22

23 Based on the results of this pilot study, we hypothesize that thiamine combined
24 with folic acid supplementation may improve cognitive function in patients with MHD
25 and provide a prognostic benefit. This needs to be confirmed by a larger sample size
26 randomized controlled multi-center clinical study.
27
28
29
30

31 **Rationale**

32
33
34 Recently, the relationship between cognitive dysfunction and oxidative stress has
35 been discussed in chronic kidney disease patients, especially dialysis patients^[1]. Our
36 previous animal study found that the cognitive function of uremia rats which was
37 assessed by the radial arm water maze test decreased compared with the sham operation
38 group. Histological assessment suggested indicated increased oxidation in the
39 hippocampal neurons and decreased numbers of neurons compared to control mice.
40 This finding is similar to previous studies^[3].
41
42
43
44
45
46
47
48

49 Thiamine and folic acid belong to the family of water-soluble B vitamins^[4].
50 Thiamine is vitamin B1, which plays an important role in reducing the production of
51 reactive oxygen species in the nervous system and alleviating oxidative stress as the
52 cofactor of transketolase^[5, 6]. Folic acid, is also called as vitamin B9, involved in the
53 synthesis of purine and thymine, metabolism of amino acid, as well as hemoglobin
54 production. Folic acid has a direct antioxidant effect, interacts with endothelial nitric
55
56
57
58
59
60

1
2
3
4 oxide synthase, and affects the bioavailability of nitric oxide cofactors. Moreover, folic
5 acid is essential for the metabolism of homocysteine into methionine, which can reduce
6 homocysteine levels^[7].
7
8
9

10 More important, clinical studies have reported that the application of vitamins B
11 including thiamine and folic acid can reduce the level of oxidative stress index
12 including homocysteine in blood^[7,8], thereby reducing oxidative stress and bringing
13 benefits to the treatment of cardiovascular complications in patients with ESRD^[9],
14 particularly in those intensive treatment or with a drop in homocysteine levels of more
15 than 20 percent^[8]. Nevertheless, recent systematic review and Meta-Analysis indicated
16 that thiamine or folic acid alone can not improves cognitive function healthy older
17 people^[10,11].
18
19
20
21
22
23
24
25
26

27 However, it is not clear whether supplementation with thiamine and folic acid, can
28 improve cognitive function in ESRD patients? Therefor, we designed this prospective,
29 randomized, placebo-controlled, double-blind, multi-center trial to explore whether the
30 intensive combination of thiamine and folic acid can improve cognitive function in
31 MHD patients with CI. The dose of thiamine (90mg/d) is according to the treatment
32 dose of Wernicke's encephalopathy^[12] and refeeding syndrome^[13]. The dose of folic
33 acid (30mg/d) is refer to the treatment of cardiovascular complications in MHD
34 patients^[8].
35
36
37
38
39
40
41
42

43 **Objectives**

44
45
46 The primary objective of this trial is to verify the hypothesis that thiamine
47 combine with folic acid supplements can improve cognitive function and prognosis in
48 MHD patients with cognitive impairment, and to provide evidence-based for clinical
49 treatment of this complication.
50
51
52
53

54 **Trial design**

55
56
57 This is a prospective, randomized, placebo-controlled, double-blind, multi-center trial.
58 It has two parallel groups with equal allocation including treatment group (Thiamine
59
60

1
2
3
4 90mg/day combined with folic acid 30mg/day) and control group (Thiamine placebo
5 90mg/day combined with folic acid placebo 30mg/day). The random envelope method
6 was used for center randomization. We used the SPIRIT reporting guidelines^[14] in the
7 current study.
8
9
10

11 12 13 14 15 **METHODS AND ANALYSIS**

16 17 18 **Study setting**

19
20
21 The current trial will be carried out simultaneously in three centers, Renji Hospital,
22 School of Medicine, Shanghai Jiao Tong University (primary center), East branch of
23 Shanghai Sixth People's Hospital (sub-center) and Shanghai Songjiang District Central
24 Hospital (sub-center). In addition, researchers from these three centers have obtained
25 GCP certificates.
26
27
28
29

30
31 In total, nearly 600 MHD patients were follow up at Ren Ji hospital. These three
32 centers have a total of about 1000 MHD patients . According to the results of our
33 previous studies, the incidence rate of cognitive impairment in MHD patients is about
34 51.6%, so there are enough patients for screening in this study. Patient recruitment will
35 begin imminently and is planned to last 3-6 months.
36
37
38
39

40 41 42 **Eligibility criteria**

43
44 The target population of this study is patients undergoing maintenance
45 hemodialysis, who should fulfil the following eligibility criteria.
46
47
48

49 50 **Inclusion criteria**

- 51 1. Maintenance hemodialysis patients (≥ 3 months)
 - 52 2. With cognitive impairment, defined as: MoCA score is less than 26, or MoCA
53 scores is less than 25 if duration of education is less than or equal to 12 years
 - 54 3. 18-75 years old, male or female
- 55
56
57
58
59
60

- 1
- 2
- 3
4. Sign the informed consent form
- 5

6 **Exclusion criteria**

- 7
- 8
- 9 1. Unable to cooperate and complete the study
- 10
- 11 2. Life expectancy is less than 1 year
- 12
- 13 3. Participated in other clinical trials within three months
- 14
- 15 4. Accompanied by severe anemia, infection, tumor, activity bleeding or heart, liver
- 16 and lung disease
- 17
- 18 5. Thiamine or folic acid allergies
- 19
- 20 6. Disorders that may cause cognitive impairment, such as stroke
- 21
- 22 7. Pregnant or lactating women
- 23
- 24 8. Subjects judged by the investigator to be unsuitable for inclusion in this study
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32

33 **Intervention**

34 An overview of the trial is provided in figure 1. The researchers screened subjects
35 according to inclusion criteria and exclusion criteria, after which the subject is
36 randomized to the treatment or the control arm by 1:1.
37

38 In the treatment arm, the subjects were treated with thiamine (90mg/day) and folic acid
39 (30mg/day).
40

41 In the control arm, the subjects were treated with thiamine placebo (90mg/day)
42 and folic acid placebo (30mg/day).
43

44 All subjects were followed up every 24 weeks for 96 weeks (table 1). As the trial
45 proceeds, statistical monitoring and concomitant projects may identify need for
46 revisions to the intervention.
47

48 **Observation item**

1
2
3
4 Demographic data of subjects at baseline were collected including age (year),
5 gender, height(cm), weight (Kg), history of smoking (Smoke every day, no matter how
6 many cigarettes), alcohol abuse (Drink alcohol every day, no matter how much), history
7 of drug abuse (drug dependence, no matter how much), history of education (year, High
8 school is defined as duration of education is more than or equal to 12 years), income
9 (yuan/year, the annual income is more than or less than 30,000 yuan), medical expenses
10 (yuan/year), cognitive impairment family history and work status (Full-time or part-
11 time jobs/retire).
12
13
14
15
16
17
18
19

20 The medical history of the patients, such as the primary cause of MHD,
21 hypertension, diabetes, cardiovascular disease, cerebrovascular disease, cirrhosis,
22 chronic obstructive pulmonary disease, the date of initiate dialysis, Average weekly
23 urine volume (mL/day), as well as folic acid, vitamin B12, active vitamin D and
24 intravenous iron therapy In the last six months.
25
26
27
28
29

30 The following information of haemodialysis treatment was collected at baseline,
31 24 weeks, 48 weeks, 72 weeks and 96 weeks of follow-up: dialysis duration (h/session),
32 dialysis frequencies (time/week), dialysis modality (HD or HDF, which is the main
33 dialysis modality, for example: HD twice a week and HDF once a week HD means
34 HD), vascular access (fistula or catheter), average weekly ultrafiltration (L/session),
35 hypotension during dialysis treatment in the last week (definition of hypotension:
36 systolic pressure <90 mmHg or diastolic pressure <60 mmHg), use low molecular
37 heparin, weight of pre and post haemodialysis (Kg), blood pressure (BP) of pre and post
38 haemodialysis (mmHg), heart rate of pre and post haemodialysis (BPM).
39
40
41
42
43
44
45
46
47
48

49 Laboratory examination data at baseline, 24 weeks, 48 weeks, 72 weeks and 96 weeks
50 of follow-up, such as white blood cell (WBC), haemoglobin (Hb), platelet (Plt), ALT,
51 AST, total protein (TP), total bilirubin (TB), PH, HCO_3^- , K^+ , Na^+ , Cl^- , albumin (Alb),
52 total cholesterol (TC), Triglyceride (TG), LDL, HDL, Calcium, Phosphorus, iPTH,
53 ferritin, fasting blood glucose (Glu), C-reactive protein (CRP), β_2 -microglobulin (β
54 $_2$ -MG), B natriuretic peptides (BNP), thiamine, folic acid and homocysteine were
55
56
57
58
59
60

1
2
3
4 collected. Transferrin saturation (TSAT) and dialysis adequacy (spKt/V) were
5
6 calculated.

7
8 Cognitive function including MoCA^[15], MMSE^[16] and ADAS-Cog^[17,18] were
9
10 assessed at baseline, 48 weeks and 96 weeks of follow-up.

11
12
13 Imageological examination including cranial functional magnetic resonance
14
15 imaging (fMRI) was performed at baseline and 96 weeks of follow-up.

16 17 18 **Endpoints**

19 20 **Primary endpoint**

21
22
23 The primary endpoint is the comparison of ADAS-Cog score between the
24
25 treatment group and the control group at 96 weeks of follow-up.

26 27 28 **Secondary endpoints**

29
30 The secondary endpoint are listed below:

- 31
32
33 1. The comparison of serum thiamine, folate, and homocysteine levels between the
34
35 treatment and control groups at 96 weeks of follow-up.
- 36
37
38 2. The comparison of cranial functional magnetic resonance imaging between
39
40 treatment group and control group at 96 weeks of follow-up.
- 41
42
43 3. Prognosis comparison between treatment group and control group at 96 weeks of
44
45 follow-up.

46 47 48 **Safety endpoints**

49
50
51 Changes in laboratory safety indicators and incidence of adverse events between
52
53 the treatment and control groups during follow-up.

54 55 56 **Withdrawal and drop-out**

57
58 Shedding criteria
59
60

1. The researchers found serious safety problems
2. The effect was so poor that there was no need to continue the trial

Exit criteria

1. Subjects who meet the inclusion criteria and do not complete the study for any reason are considered to be withdrawal subjects, which include subjects' self-withdrawal and subjects' withdrawal determined by the investigator
2. Severe adverse events occurred and the investigator considered it appropriate to withdraw from the study
3. Major Trial Protocol Deviation Subjects are found to not meet the requirements of the trial protocol after randomization
4. Serious other complications occurred during the clinical trial, and the investigators determined that it would not be beneficial to continue the study
5. Unplanned pregnancy
6. Lost follow-up, subjects did not return to the center, and contact with subjects failed

If a subject is lost to follow-up, the investigator should make every effort to contact the subject and encourage the subject to continue to participate in the study as planned. If the subject withdraws their informed consent, the researcher should not evaluate the subject further and should not attempt to collect more data.

For subjects who withdraw from the trial early, the last interview should be arranged within 3 days after the withdrawal (the content of the interview should be determined by the investigator according to the actual situation of the subjects) to complete the efficacy and safety assessment.

Even if the subject is unable to return to the study center for visits, the investigator will complete all available data on the Case Report Form (CRF) and record the reason

1
2
3
4 for early withdrawal. Whenever possible, the subject must return all drugs. The
5 investigator will take inventory of the drug and complete the Drug Release and Recall
6 Record Form.
7
8
9

10 **Participant timeline**

11
12
13 Please refer to figure 1 for details of the visit schedule and participant timeline.
14
15

16 **Sample size and recruitment**

17
18 Based on the previous single-center study, it was assumed that cognitive function
19 (MoCA score) in the treatment group improved from 20 to 26, and set $\alpha=0.05$ and
20 $1-\beta=0.9$, then at least 100 patients per group are required. In consideration of
21 control shedding or rejection rate within 15% during the test and subsequent analysis
22 requirements, 115 cases were planned to be enrolled in each group. The ratio of the
23 treatment group to the control group was 1:1, with 115 cases in the treatment group and
24 115 cases in the control group. This study will screen and enroll patients on
25 maintenance hemodialysis in three research centers.
26
27
28
29
30
31
32

33 **Randomisation**

34
35 The central randomization method will be adopted in this study and the principles
36 of placebo-controlled, double-blind randomized control will be followed. All eligible
37 subjects will be randomised in a ratio of 1:1 and divided into the treatment and control
38 arms.
39
40
41
42

43 Randomization sequence was generated by an independent data manager using
44 SAS (version 9.3) and stored within sealed opaque envelopes. The investigator opened
45 an envelope to obtain a number every time a patient was consented to enter the trial.
46 Based on this number, the patient is assigned the corresponding number of medication
47 (Treatment drugs or placebos).
48
49
50
51

52 **Blind and unblind**

53
54
55 This is a prospective, randomized, placebo-controlled, double-blind, multi-center
56 trial. This study will establish the program of blind setting and blind breaking. There
57 were both blind and non-blind drug administrators in this study. To ensure the
58
59
60

1
2
3
4 indistinguishable nature of the investigational drug, the blind drug administrator will
5 confirm the indistinguishable nature of the investigational drug and its matching
6 placebo in terms of appearance, taste, etc., before the investigational drug is distributed
7 and unblinded. The non-blind drug administrator creates a master random list of drugs
8 and creates a code break blind authorization number for emergency code break blind.
9
10 The non-blind drug administrator will securely store the master random list and the
11 code broken blind authorization number list until unblinding. The investigator will
12 develop and maintain a written emergency code blinding procedure to be followed in
13 response to an emergency.
14
15
16
17
18
19
20

21 **Selected data collection methods**

22
23
24 Cognitive function scores including MoCA, MMSE and ADAS-Cog will be
25 performed by board certified neurologists whenever possible. All cognitive function
26 scores will be performed before or during the interval of hemodialysis.
27
28
29

30 **Data statement**

31
32 The investigator must properly handle all the data obtained during the clinical trial,
33 and truthfully record all adverse events and serious adverse events during the clinical
34 trial, so as to ensure the rights and privacy of the subjects participating in the clinical
35 trial. Personal information of subjects will be collected, shared and maintained to
36 protect confidentiality during and after the study. Only the project investigator will have
37 access to the final trial data set.
38
39
40
41
42

43 A data monitoring committee (DMC) is composed of clinicians and
44 biostatisticians from Clinical Center for Investigation, Renji Hospital, School of Medicine,
45 Shanghai Jiao Tong University who are not involved in this study for the purpose of
46 ensuring the safety of subjects and the quality of study data.
47
48
49
50

51 **Statistical methods**

52 **Data Set Category**

- 53
54
55
56 1. Full Analysis Set(FAS): the case of using at least once drugs and main efficacy
57 indexes data after the drug administered.
58
59
60

- 2.
3. Per Protocol Set(PPS): the good compliance case of meeting the main inclusion and exclusion criteria without affecting the main curative effect of prohibiting drugs during the trial.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.
- 42.
- 43.
- 44.
- 45.
- 46.
- 47.
- 48.
- 49.
- 50.
- 51.
- 52.
- 53.
- 54.
- 55.
- 56.
- 57.
- 58.
- 59.
- 60.

Statistical analysis technique

It will be listed separately that the number of subjects selected and completed the follow-up in the population and centers, identifying three analysis data sets (FAS, PPS, SS) as specified above. The primary analysis only included patients with completed primary outcomes. The comparisons among ADAS-Cog scores and other secondary outcomes over time within subjects was conducted by using repeated measure ANOVA, and pairwise t-test with Bonferroni adjustment was performed for multiple comparisons. On the other hand, for comparisons between treatment and control group, simple one-way ANOVA or Wilcoxon rank sum test was used. The chisquare method was used for statistical analysis of the categorical data. For missing data in secondary efficacy outcomes, they were assumed to be missing at random and multiple imputation was conducted. Kaplan-Meier survival curve was used for survival analysis.

Variables of normal distribution were presented by means with SD while skewed ones were reported as the median and the inter-quartile ranges. Counting data were expressed as constituent ratios or percentages.

A $p < 0.05$ was considered statistically significant difference. Statistical analyses were conducted with SPSS (Version 20.0, SPSS Inc., Chicago, IL, USA).

Harms

Safety endpoints related directly to changes in laboratory safety indicators and incidence of adverse events between the treatment and control groups during follow-up. These endpoints will be listed according to treatment received with a breakdown. Subjects will be followed up in detail, if any complications arise, appropriate treatment will be provided in accordance with current routine medical procedures.

Patient and Public Involvement statement

1
2
3
4 The trial protocol was developed in part by nephrological and neurological
5 physicians with years of experience in treating MHD patients with CI. At the same time,
6 medical statisticians performed study design and sample size estimation. Patients and
7 the public have not yet been involved directly in the design, or conduct, or reporting,
8 or dissemination plans of this trail protocol.
9
10
11
12

13 14 **Ethics and dissemination**

15
16
17 This trial has been approved by Shanghai Jiao Tong University School of
18 Medicine, Renji Hospital Ethics Committee (KY2019-199). Other participating sub-
19 centers must also obtain ethics committee approval documents prior to the start of
20 clinical trials. The Good Clinical Practice(GCP)^[19] regulations shall be strictly followed
21 during the test implementation. This trial has been registered with the Chinese Clinical
22 Trial Registry (<http://www.chictr.org.cn/index.aspx>) at 22 Jan. 2020. Trial registration
23 number is ChiCTR2000029297. Amendments to the protocol will be reviewed by
24 Ethics Committees. Informed consent will be obtained before collecting any patient
25 data and patient information. After publication of study results, trial report will be
26 published in peer-reviewed journals and/or in national or international conferences. All
27 researchers involved in the design, discussion and writing of this study protocol, as the
28 authors.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **DISCUSSION**

45
46 Epidemiological study shows the number of dialysis patients is expected to rise to
47 2.162 million by 2030 in Asia^[20]. Meanwhile, cognitive impairment is a common
48 complications in ESRD patients^[1]. In pilot study, we enrolled 50 maintenance
49 hemodialysis patients with cognitive impairment, including the treatment group (n=25)
50 who received thiamine 90mg/day combined with folic acid 30mg/day and the control
51 group (n=25) who was the blank control group. After 2 years of follow-up, cognitive
52 function which was evaluated by MOCA score was significantly improved in the
53
54
55
56
57
58
59
60

1
2
3
4 treatment group. In addition, there was no statistically significant difference in safety
5
6 between the two groups.
7

8
9
10 Based on the results of this pilot study, we designed this prospective, randomized,
11 placebo-controlled, double-blind, multi-center trial. In this study, MHD patients with
12 CI from several large-scale hemodialysis centers in Shanghai were enrolled in a
13 prospective, randomized, controlled, double-blind study. According to the sample size
14 of the pilot study, 230 subjects were expected to be enrolled. The subjects were
15 randomly divided into treatment group (n=115, thiamine 90mg/day combined with folic
16 acid 30mg/day) and control group (n=115, thiamine placebo 90mg/day combined with
17 folic acid placebo 30mg/day) and followed up for 96 weeks. Cognitive function scores,
18 serum levels of thiamine, folate and homocysteine, functional magnetic resonance
19 imaging of the brain, and safety measures were monitored regularly.
20
21
22
23
24
25
26
27
28

29
30 This study hopes to verify added thiamine and folic acid reduces homocysteine
31 levels, so as to relieve the oxidative stress and improve cognitive function in patients
32 with MHD. To explore the benefits of supplementation with thiamine and folic acid in
33 the prognosis of MHD patients with CI. To evaluate the safety of thiamine and folic
34 acid in MHD patients. This study may provides evidence-based evidence for the clinical
35 treatment of this complication and ultimately lays a foundation for the organization and
36 implementation of higher level clinical research in this field.
37
38
39
40
41
42

43
44 This exploratory study would be conducted to evaluate the efficacy of thiamine
45 and folic acid supplement in the treatment of MHD patients complicated with CI, so as
46 to help clinically find an effective treatment for this complication and reach the leading
47 domestic and international level. It is helpful to promote the cross-collaboration and
48 common development of multi-centers and multi-disciplines, improve the ability and
49 level of the treatment of nervous system complications in MHD patients, and lay a
50 foundation for the organization and implementation of higher level clinical research in
51 this field.
52
53
54
55
56
57
58
59
60

1
2
3
4 Through this study, a breakthrough can be achieved in the treatment of MHD
5 patients complicated with CI, blocking the disease progression of MHD patients,
6 reducing the hospitalization rate, medical costs and mortality of MHD patients caused
7 by CI, improving the quality of life of MHD patients, thus improving the prognosis,
8 and having a good clinical application prospect.
9
10
11
12
13
14
15
16

17 **Acknowledgements**

18
19 We would like to thank East branch of Shanghai Sixth People's Hospital and Shanghai
20 Songjiang District Central Hospital for their contribution to the revision of the study
21 protocol as participating research centers.
22
23
24
25

26 **Author Contributors**

27
28 Renhua Lu and Leyi Gu were responsible for the design of the entire study, including
29 the drafting, revision and submission of clinical trial protocols. Weiming Zhang,
30 Yongping Guo, Xiujuan Zang, Huihua Pang, Shang Liu, Kewei Xie, Ping Li and
31 Xiaojun Zeng are responsible for the discussion and revision of clinical trial protocol.
32 Yan Zhou is responsible for designing the imaging tests. Ling Yu takes charge of the
33 design of cognitive function tests. Shuting Pan is responsible for the design of statistical
34 methods. Yifei Lu is in charge of the pharmacological mechanisms and dosage selection
35 of experimental drugs. All authors have read and approved the final manuscript.
36
37
38
39
40
41
42
43
44
45

46 **Funding**

47
48 The clinical trial was supported by the 2017 Clinical research innovation training fund
49 of Renji Hospital, School of Medicine, Shanghai Jiao Tong University under Grant
50 PYIII-17-028; 2019 Special fund for clinical medical research of Chinese medical
51 association under Grant 18020030782; 2019 Research seed fund training program of
52 Renji Hospital, School of Medicine, Shanghai Jiao Tong University under Grant
53 RJZZ19-004 and Clinical Research Plan of Shanghai Hospital Development Center
54
55
56
57
58
59
60

1
2
3
4 under Grant SHDC2020CR4004.
5

6 **Competing interests** None declared.
7

8
9 **Word count** 4769.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Lu R, Kiernan MC, Murray A, Rosner MH, Ronco C. Kidney-brain crosstalk in the acute and chronic setting. *Nature Reviews Nephrology*. 2015;11(12):707-719.
2. Lu R, Xu C, Li Y, Yu L, Shao X, Xie K, et al. The Incidence Prognosis and Risk Factors of Cognitive Impairment in Maintenance Haemodialysis Patients. *Blood Purification*. 2019;47,:101-108.
3. Fujisaki K, Tsuruya K, Yamato M, Toyonaga J, Noguchi H, Nakano T, et al. Cerebral oxidative stress induces spatial working memory dysfunction in uraemic mice: neuroprotective effect of tempol. *Nephrol Dial Transplant*. 2014;29:529-538.
4. Alan S Hazell, Roger F Butterworth. Update of cell damage mechanisms in thiamine deficiency: focus on oxidative stress, excitotoxicity and inflammation. *Alcohol Alcohol*. 2009; 44: 141-147.
5. Calingasan NY, Chun WJ, Park LC et al. Oxidative stress is associated with region-specific neuronal death during thiamine deficiency. *J Neuropathol Exp Neurol*. 1999; 58: 946-958.
6. Langlais PJ, Anderson G, Guo SX et al. Increased cerebral free radical production during thiamine deficiency. *Metab Brain Dis*. 1997; 12: 137-143.
7. Stanger O. Physiology of folic acid in health and disease. *Curr Drug Metab*. 2002; 3: 211-223.
8. Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, et al. Folic Acid Therapy and Cardiovascular Disease in ESRD or Advanced Chronic Kidney Disease: A Meta-Analysis. *Clin J Am Soc Nephrol*. 2011;6:482-488.
9. Rex L Jamison, Pamela Hartigan, James S Kaufman, David S Goldfarb, Stuart R Warren, Peter D Guarino, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a

1
2
3
4 randomized controlled trial, JAMA. 2007); 298(10):1163-1170.

5
6
7 10. Koh F, Charlton K, Walton K, McMahon AT. Role of Dietary Protein and Thiamine
8 Intakes on Cognitive Function in Healthy Older People: A Systematic Review.
9 Nutrients. 2015;7(4):2415-2439.

10
11
12
13 11. Ford AH, Almeida OP. Effect of Vitamin B Supplementation on Cognitive Function
14 in the Elderly: A Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(5):419-
15 434.

16
17
18
19 12. Michael W Donnino, Jose Vega, Joseph Miller, Mark Walsh. Myths and
20 misconceptions of Wernicke's encephalopathy: what every emergency physician
21 should know. Ann Emerg Med. 2007;50:715-721.

22
23
24
25 13. Fuentebella J, Kerner JA. Refeeding syndrome. Pediatr Clin North Am. 2009;
26 56:1201-1210.

27
28
29
30
31 14. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K,
32 Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D.
33 SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials.
34 BMJ. 2013;346:e7586.

35
36
37
38
39 15. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment,
40 MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;
41 53:695-699.

42
43
44
45 16. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for
46 grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-
47 198.

48
49
50
51 17. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am
52 J Psychiatry. 1984; 141(11):1356-1364.

53
54
55
56 18. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an
57

1
2
3
4 instrument for assessing treatment efficacy. *Psychopharmacol Bull.* 1983; 19(3):448-
5 450.

6
7
8 19. Good Clinical Practice (GCP) Instructions of National Medical Products
9 Administration of PR. China.
10 <https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200426162401243.html>. Accessed Apr
11 2020.
12
13
14

15
16
17 20. Thaminda Liyanage, Toshiharu Ninomiya, Vivekanand Jha, Bruce Neal, Halle
18 Marie Patrice, Ikechi Okpechi, et al. Worldwide access to treatment for end-stage
19 kidney disease: a systematic review. *Lancet.* 2015; 385(9981): 1975-1982.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 The visit schedule of this study

	screen	Randomization	Follow-up period			
Visiting period (weeks)		T0	T1	T2	T3	T4
	-4	0	24±4	48±4	72±4	96±4
Informed consent	×					
Inclusion and Exclusion Criteria	×					
Demographic data	×					
Medical history	×					
Information of haemodialysis	×		×	×	×	×
Laboratory examination	×		×	×	×	×
Cognitive function	×			×		×
Imageological examination	×					×
Drug Administration		×	×	×	×	×
Adverse Event	×	×	×	×	×	×

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 An overview of this trial

338x190mm (96 x 96 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	12
Protocol version	#3	Date and version identifier	2

1	Funding	#4	Sources and types of financial, material, and other support	14,15
2				
3				
4				
5	Roles and	#5a	Names, affiliations, and roles of protocol contributors	14
6	responsibilities:			
7	contributorship			
8				
9				
10				
11	Roles and	#5b	Name and contact information for the trial sponsor	n/a, no
12	responsibilities:			sponsor
13	sponsor contact			
14	information			
15				
16				
17				
18				
19	Roles and	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	n/a, no
20	responsibilities:			sponsor and
21	sponsor and funder			funder
22				
23				
24				
25				
26				
27				
28				
29				
30	Roles and	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	n/a, no
31	responsibilities:			committees
32	committees			
33				
34				
35				
36				
37				
38				
39				
40				
41	Introduction			
42				
43				
44	Background and	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3,4
45	rationale			
46				
47				
48				
49				
50				
51	Background and	#6b	Explanation for choice of comparators	4,5
52	rationale: choice of			
53	comparators			
54				
55				
56				
57	Objectives	#7	Specific objectives or hypotheses	4,5
58				
59				
60				

1	Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	5
2				
3				
4				
5				
6				
7				
8	Methods:			
9	Participants, interventions, and outcomes			
10				
11				
12				
13				
14				
15				
16	Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
17				
18				
19				
20				
21				
22				
23				
24	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5,6
25				
26				
27				
28				
29				
30				
31	Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6
32				
33				
34				
35				
36				
37				
38	Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	8,9
39				
40				
41				
42				
43				
44				
45	Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	6,7
46				
47				
48				
49				
50				
51	Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	8,9
52				
53				
54				
55				
56	Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	7,8
57				
58				
59				
60				

pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

1			
2			
3			
4			
5			
6			
7			
8			
9	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) 9
10			
11			
12			
13			
14			
15			
16			
17	Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations 9
18			
19			
20			
21			
22			
23			
24	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size 9
25			
26			
27			
28			
29	Methods:		
30	Assignment of		
31	interventions (for		
32	controlled trials)		
33			
34			
35			
36			
37	Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions 9,10
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49	Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 9,10
50			
51			
52			
53			
54			
55			
56	Allocation:	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 9,10
57			
58			
59			
60			

1	implementation	interventions	
2			
3	Blinding (masking)	#17a Who will be blinded after assignment to interventions	10
4		(eg, trial participants, care providers, outcome	
5		assessors, data analysts), and how	
6			
7			
8			
9	Blinding (masking):	#17b If blinded, circumstances under which unblinding is	10
10	emergency unblinding	permissible, and procedure for revealing a	
11		participant's allocated intervention during the trial	
12			
13			
14			
15	Methods: Data		
16	collection,		
17	management, and		
18	analysis		
19			
20			
21			
22			
23	Data collection plan	#18a Plans for assessment and collection of outcome,	6,7
24		baseline, and other trial data, including any related	
25		processes to promote data quality (eg, duplicate	
26		measurements, training of assessors) and a	
27		description of study instruments (eg, questionnaires,	
28		laboratory tests) along with their reliability and validity,	
29		if known. Reference to where data collection forms	
30		can be found, if not in the protocol	
31			
32			
33			
34			
35			
36			
37	Data collection plan:	#18b Plans to promote participant retention and complete	8,9
38	retention	follow-up, including list of any outcome data to be	
39		collected for participants who discontinue or deviate	
40		from intervention protocols	
41			
42			
43			
44	Data management	#19 Plans for data entry, coding, security, and storage,	10
45		including any related processes to promote data	
46		quality (eg, double data entry; range checks for data	
47		values). Reference to where details of data	
48		management procedures can be found, if not in the	
49		protocol	
50			
51			
52			
53			
54			
55	Statistics: outcomes	#20a Statistical methods for analysing primary and	11
56		secondary outcomes. Reference to where other details	
57		of the statistical analysis plan can be found, if not in	
58			
59			
60			

the protocol

1			
2			
3	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup
4	analyses		and adjusted analyses)
5			
6			
7			
8	Statistics: analysis	#20c	Definition of analysis population relating to protocol
9	population and		non-adherence (eg, as randomised analysis), and any
10	missing data		statistical methods to handle missing data (eg, multiple
11			imputation)
12			
13			
14			
15	Methods:		
16	Monitoring		
17			
18			
19			
20	Data monitoring:	#21a	Composition of data monitoring committee (DMC);
21	formal committee		summary of its role and reporting structure; statement
22			of whether it is independent from the sponsor and
23			competing interests; and reference to where further
24			details about its charter can be found, if not in the
25			protocol. Alternatively, an explanation of why a DMC is
26			not needed
27			
28			
29			
30			
31			
32	Data monitoring:	#21b	Description of any interim analyses and stopping
33	interim analysis		guidelines, including who will have access to these
34			interim results and make the final decision to terminate
35			the trial
36			
37			
38			
39			
40	Harms	#22	Plans for collecting, assessing, reporting, and
41			managing solicited and spontaneously reported
42			adverse events and other unintended effects of trial
43			interventions or trial conduct
44			
45			
46			
47			
48	Auditing	#23	Frequency and procedures for auditing trial conduct, if
49			any, and whether the process will be independent from
50			investigators and the sponsor
51			
52			
53			
54	Ethics and		
55	dissemination		
56			
57			
58			
59			
60			

1	Research ethics	#24	Plans for seeking research ethics committee /	12
2	approval		institutional review board (REC / IRB) approval	
3				
4				
5	Protocol amendments	#25	Plans for communicating important protocol	12
6			modifications (eg, changes to eligibility criteria,	
7			outcomes, analyses) to relevant parties (eg,	
8			investigators, REC / IRBs, trial participants, trial	
9			registries, journals, regulators)	
10				
11				
12				
13				
14	Consent or assent	#26a	Who will obtain informed consent or assent from	12
15			potential trial participants or authorised surrogates,	
16			and how (see Item 32)	
17				
18				
19				
20				
21	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a, not
22	ancillary studies		participant data and biological specimens in ancillary	applicable
23			studies, if applicable	
24				
25				
26				
27	Confidentiality	#27	How personal information about potential and enrolled	10
28			participants will be collected, shared, and maintained	
29			in order to protect confidentiality before, during, and	
30			after the trial	
31				
32				
33				
34				
35	Declaration of	#28	Financial and other competing interests for principal	15
36	interests		investigators for the overall trial and each study site	
37				
38				
39	Data access	#29	Statement of who will have access to the final trial	10
40			dataset, and disclosure of contractual agreements that	
41			limit such access for investigators	
42				
43				
44				
45	Ancillary and post trial	#30	Provisions, if any, for ancillary and post-trial care, and	11
46	care		for compensation to those who suffer harm from trial	
47			participation	
48				
49				
50				
51	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate	12
52	trial results		trial results to participants, healthcare professionals,	
53			the public, and other relevant groups (eg, via	
54			publication, reporting in results databases, or other	
55			data sharing arrangements), including any publication	
56				
57				
58				
59				
60				

restrictions

1			
2			
3	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use
4	authorship		of professional writers
5			
6			
7			
8	Dissemination policy:	#31c	Plans, if any, for granting public access to the full
9	reproducible research		protocol, participant-level dataset, and statistical code
10			
11			

Appendices

12			
13			
14			
15			
16	Informed consent	#32	Model consent form and other related documentation
17	materials		given to participants and authorised surrogates
18			n/a, not applicable
19			
20	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage
21			of biological specimens for genetic or molecular
22			analysis in the current trial and for future use in
23			ancillary studies, if applicable
24			
25			
26			
27			

28 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative
 29 Commons Attribution License CC-BY-NC. This checklist can be completed online using
 30 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
 31 [Penelope.ai](#)
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Protocol for thiamine and folic acid in the treatment of cognitive impairment in maintenance hemodialysis patients: A prospective, randomized, placebo-controlled, double-blind, multi-center study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050605.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Sep-2021
Complete List of Authors:	Lu, Renhua; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Gu, Le-yi; Shanghai Jiao Tong University, Department of Nephrology; Shanghai Jiao Tong University, Department of Nephrology Zhang, Weiming; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Guo, Yongping; Shanghai Sixth Peoples Hospital, Department of Nephrology Zang, Xiujuan; Shanghai Songjiang District Central Hospital, Department of Nephrology Zhou, Yan; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Radiology Yu, Ling; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Neurology Pan, Shuting; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Clinical Center for Investigation Pang, Huihua; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Liu, Shang; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Xie, Kewei; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Li, Ping; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Zeng, Xiaojun; Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Department of Nephrology Lu, Yifei; Shanghai University of Traditional Chinese Medicine, Department of pharmacy
Primary Subject Heading:	Urology
Secondary Subject Heading:	Neurology
Keywords:	End stage renal failure < NEPHROLOGY, Delirium & cognitive disorders < PSYCHIATRY, Clinical trials < THERAPEUTICS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4 **Protocol for thiamine and folic acid in the treatment of cognitive**
5
6 **impairment in maintenance hemodialysis patients: A prospective,**
7
8 **randomized, placebo-controlled, double-blind, multi-center study**

9
10
11 Renhua Lu¹, Leyi Gu^{1,2*}, Weiming Zhang¹, Yongping Guo³, Xiujuan Zang⁴, Yan Zhou⁵,
12
13 Ling Yu⁶, Shuting Pan², Huihua Pang¹, Shang Liu¹, Kewei Xie¹, Ping Li¹, Xiaojun Zeng¹,
14
15 Yifei Lu⁷

16
17
18
19 1 Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
20
21 Shanghai, China

22
23 2 Clinical Center for Investigation, Renji Hospital, School of Medicine, Shanghai Jiao Tong
24
25 University, Shanghai, China

26
27 3 Department of Nephrology, East branch of Shanghai Sixth People's Hospital, Shanghai, China

28
29 4 Department of Nephrology, Shanghai Songjiang District Central Hospital, Shanghai, China

30
31 5 Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
32
33 Shanghai, China

34
35 6 Department of Neurology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
36
37 Shanghai, China

38
39 7 Department of pharmacy, Shanghai University of Traditional Chinese Medicine

40
41 *Correspondence: Leyi Gu, Department of Nephrology, Renji Hospital, 160 Pujian Road,
42
43 Shanghai, China. E-Mail guleyi@aliyun.com

44
45
46 **ABSTRACT**

47
48 **Introduction**

49
50 Cognitive impairment (CI) is the common complications in maintenance hemodialysis (MHD)
51
52 patients. Recently, the pathogenesis of CI has been discussed and oxidative stress is one of the main
53
54 mechanisms in these patients. Thiamine and folic acid, which play an important role in relieving the
55
56 production of reactive oxygen species, reducing homocysteine levels, improving oxidative stress in
57
58 the nervous system. In pilot study, cognitive function was significantly improved in the group with
59
60

1
2
3
4 thiamine and folic supplementation. Based on this result, we hypothesize that thiamine combined
5
6 with folic acid supplementation may improve cognitive function in patients with MHD.

7 **Methods and analysis** In this prospective, randomized, placebo-controlled, double-blind, multi-
8
9 center study, we will enroll patients undergoing hemodialysis who has the Montreal Cognitive
10
11 Assessment (MoCA) score lower than 26 to treatment group (thiamine 90mg/day combined with
12
13 folic acid 30mg/day) or control group (thiamine placebo 90mg/day combined with folic acid placebo
14
15 30mg/day). All subjects will be followed up for 96 weeks. The primary endpoint is the comparison
16
17 of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score between
18
19 treatment group and control group at 96 weeks of follow-up. The secondary endpoints include serum
20
21 thiamine, folate, homocysteine levels, cranial functional magnetic resonance imaging, and survival.
22
23 The central randomization method will be adopted and the principles of placebo-controlled, double-
24
25 blind randomized control will be followed. The comparisons among ADAS-Cog scores and other
26
27 secondary endpoints over time within subjects is conducted by using repeated measure ANOVA or
28
29 generalized estimating equations (GEE). Pairwise t-test with Bonferroni adjustment is performed
30
31 for multiple comparisons. On the other hand, for comparisons between treatment and control group,
32
33 simple one-way ANOVA, GEE or Wilcoxon rank sum test is used. The chisquare method is used
34
35 for statistical analysis of the categorical data. Kaplan-Meier survival curve is used for survival
36
37 analysis. A $p < 0.05$ is considered statistically significant difference.

38
39 **Keywords:** End-stage renal disease; Cognitive function; Vitamins B; Double-blind; Multi-center

40
41 **Ethics and dissemination** This trial has been approved by Shanghai Jiao Tong University School
42
43 of Medicine, Renji Hospital Ethics Committee (KY2019-199). After publication of study results,
44
45 trial report will be published in peer-reviewed journals and/or in national or international
46
47 conferences.

48
49 **Trial registration number** ChiCTR2000029297

50 51 **Strengths and limitations of this study**

- 52 ● This is a prospective, randomized, placebo-controlled, double-blind, multi-center study in
53 maintenance hemodialysis patients addressing the complication of cognitive impairment.
- 54 ● The trial includes treatment and control group.
- 55 ● It provides important 96 weeks data on cognitive function, serum thiamine, folate,
56
57 homocysteine levels, cranial functional magnetic resonance imaging, and mortality.
58
59
60

- Laboratory test and adverse events are closely monitored to ensure the safety of the study during follow-up.
- Although unified training is conducted, cognitive score measurement by different researchers may differ in the evaluation of cognitive function of subjects in a multi-center study.

INTRODUCTION

This publication describes the study design and protocol of a clinical trial on thiamine and folic acid in the treatment of cognitive impairment in maintenance hemodialysis patients: A prospective, randomized, placebo-controlled, double-blind, multi-center study (Version 2.0; Date 08 May, 2020).

Background

Cognitive impairment (CI) is one of the common neurological complications in patients with end stage renal disease (ESRD)^[1]. Our previous single-center cohort observational study showed that the incidence of CI in patients with maintenance hemodialysis (MHD) was 51.6%^[2].

As we know, acute neurological complications such as stroke which is taken seriously concern by nephrologist. However, cognitive impairment may be ignored in patients on MHD by nephrologist. At the same time, because of the dormant clinical symptoms in early cognitive impairment patients, this complication can not be timely diagnosed and treated, significantly reduce the patient's quality of life, and leads to the poor clinical prognosis. These bring to the country's social and family burden which need to cause the extensive concern of the medical profession.

In our single-center randomized controlled pilot study, 50 MHD patients with cognitive impairment were enrolled, including the treatment group (n=25, Thiamine 90mg/day combined with folic acid 30mg/day) and the control group (n=25, nonintervention). After 2 years of follow-up, cognitive function was significantly improved in the treatment group. The 2-year survival rate was also found to be better in the treatment group than in the control group. In addition, there was no statistically significant difference in safety between two groups.

1
2
3
4 Based on the results of this pilot study, we hypothesize that thiamine combined
5 with folic acid supplementation may improve cognitive function in patients with MHD
6 and provide a prognostic benefit. This needs to be confirmed by a larger sample size
7 randomized controlled multi-center clinical study.
8
9
10

11 **Rationale**

12
13 Recently, the relationship between cognitive dysfunction and oxidative stress has
14 been discussed in chronic kidney disease patients, especially dialysis patients^[1]. Our
15 previous animal study found that the cognitive function of uremia rats which was
16 assessed by the radial arm water maze test decreased compared with the sham operation
17 group. Histological assessment suggested indicated increased oxidation in the
18 hippocampal neurons and decreased numbers of neurons compared to control mice.
19 This finding is similar to previous studies^[3].
20
21
22
23
24
25
26

27 Thiamine and folic acid belong to the family of water-soluble B vitamins^[4].
28 Thiamine is vitamin B1, which plays an important role in reducing the production of
29 reactive oxygen species in the nervous system and alleviating oxidative stress as the
30 cofactor of transketolase^[5, 6]. Folic acid, is also called as vitamin B9, involved in the
31 synthesis of purine and thymine, metabolism of amino acid, as well as hemoglobin
32 production. Folic acid has a direct antioxidant effect, interacts with endothelial nitric
33 oxide synthase, and affects the bioavailability of nitric oxide cofactors. Moreover, folic
34 acid is essential for the metabolism of homocysteine into methionine, which can reduce
35 homocysteine levels^[7].
36
37
38
39
40
41
42
43
44

45 More important, clinical studies have reported that the application of vitamins B
46 including thiamine and folic acid can reduce the level of oxidative stress index
47 including homocysteine in blood^[7,8], thereby reducing oxidative stress and bringing
48 benefits to the treatment of cardiovascular complications in patients with ESRD^[9],
49 particularly in those intensive treatment or with a drop in homocysteine levels of more
50 than 20 percent^[8]. Nevertheless, recent systematic review and Meta-Analysis indicated
51 that thiamine or folic acid alone can not improves cognitive function healthy older
52 people^[10,11].
53
54
55
56
57
58
59
60

However, it is not clear whether supplementation with thiamine and folic acid, can

1
2
3
4 improve cognitive function in ESRD patients? Therefore, we designed this prospective,
5
6 randomized, placebo-controlled, double-blind, multi-center trial to explore whether the
7
8 intensive combination of thiamine and folic acid can improve cognitive function in
9
10 MHD patients with CI. The dose of thiamine (90mg/d) is according to the treatment
11
12 dose of Wernicke's encephalopathy^[12] and refeeding syndrome^[13]. The dose of folic
13
14 acid (30mg/d) is refer to the treatment of cardiovascular complications in MHD
15
16 patients^[8].

17 **Objectives**

18
19 The primary objective of this trial is to verify the hypothesis that thiamine
20
21 combine with folic acid supplements can improve cognitive function and prognosis in
22
23 MHD patients with cognitive impairment, and to provide evidence-based for clinical
24
25 treatment of this complication.
26

27 **Trial design**

28
29 This is a prospective, randomized, placebo-controlled, double-blind, multi-center
30
31 trial. It has two parallel groups with equal allocation including treatment group
32
33 (Thiamine 90mg/day combined with folic acid 30mg/day) and control group (Thiamine
34
35 placebo 90mg/day combined with folic acid placebo 30mg/day). The random envelope
36
37 method was used for center randomization. We used the SPIRIT reporting guidelines^[14]
38
39 in the current study.
40
41

42 **METHODS AND ANALYSIS**

43 **Study setting**

44
45 The current trial will be carried out simultaneously in three centers, Renji Hospital,
46
47 School of Medicine, Shanghai Jiao Tong University (primary center), East branch of
48
49 Shanghai Sixth People's Hospital (sub-center) and Shanghai Songjiang District Central
50
51 Hospital (sub-center). In addition, researchers from these three centers have obtained
52
53 GCP certificates.
54
55

56
57 In total, nearly 600 MHD patients were follow up at Ren Ji hospital. These three
58
59 centers have a total of about 1000 MHD patients. According to the results of our
60
previous studies, the incidence rate of cognitive impairment in MHD patients is about

1
2
3
4 51.6%, so there are enough patients for screening in this study. Patient recruitment will
5
6 begin imminently and is planned to last 3-6 months.

7 **Eligibility criteria**

8
9 The target population of this study is patients undergoing maintenance
10
11 hemodialysis, who should fulfil the following eligibility criteria.

12 **Inclusion criteria**

- 13 1. Maintenance hemodialysis patients (≥ 3 months)
- 14 2. With cognitive impairment, defined as: MoCA score is less than 26, or MoCA
15 scores is less than 25 if duration of education is less than or equal to 12 years
- 16 3. 18-75 years old, male or female
- 17 4. Sign the informed consent form

18 **Exclusion criteria**

- 19 1. Unable to cooperate and complete the study
- 20 2. Life expectancy is less than 1 year
- 21 3. Participated in other clinical trials within three months
- 22 4. Accompanied by severe anemia, infection, tumor, activity bleeding or heart, liver
23 and lung disease
- 24 5. Thiamine or folic acid allergies
- 25 6. Disorders that may cause cognitive impairment, such as stroke
- 26 7. Pregnant or lactating women
- 27 8. Subjects judged by the investigator to be unsuitable for inclusion in this study

28 **Intervention**

29
30 An overview of the trial is provided in figure 1. The researchers screen subjects
31 according to inclusion criteria and exclusion criteria, after which the subject is
32 randomized to the treatment or the control arm by 1:1.

33
34 In the treatment arm, the subjects are treated with thiamine tablets (10mg/tablet,
35 three tablets three times a day, 90mg/day) and folic acid tablets (5mg/tablet, two tablets
36 three times a day, 30mg/day).

37
38 In the control arm, the subjects are treated with thiamine placebo tablets
39 (10mg/tablet, three tablets three times a day, 90mg/day) and folic acid placebo tablets
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(5mg/tablet, two tablets three times a day, 30mg/day).

All subjects will be followed up every 24 weeks for 96 weeks (table 1). As the trial proceeds, statistical monitoring and concomitant projects may identify need for revisions to the intervention.

Observation item

Demographic data of subjects at baseline will be collected including age (year), gender, height(cm), weight (Kg), history of smoking (Smoke every day, no matter how many cigarettes), alcohol abuse (Drink alcohol every day, no matter how much), history of drug abuse (drug dependence, no matter how much), history of education (year, High school is defined as duration of education is more than or equal to 12 years), income (yuan/year, the annual income is more than or less than 30,000 yuan), medical expenses (yuan/year), cognitive impairment family history and work status (Full-time or part-time jobs/retire).

The medical history of the patients, such as the primary cause of MHD, hypertension, diabetes, cardiovascular disease, cerebrovascular disease, cirrhosis, chronic obstructive pulmonary disease, the date of initiate dialysis, average weekly urine volume (ml/day), as well as folic acid, vitamin B12, active vitamin D and intravenous iron therapy in the last six months will be collected.

The following information of hemodialysis treatment will be collected at baseline, 24 weeks, 48 weeks, 72 weeks and 96 weeks of follow-up: dialysis duration (h/session), dialysis frequencies (time/week), dialysis modality (HD or HDF, which is the main dialysis modality, for example: HD twice a week and HDF once a week HD means HD), vascular access (fistula or catheter), average weekly ultrafiltration (L/session), hypotension during dialysis treatment in the last week (definition of hypotension: systolic pressure <90 mmHg or diastolic pressure <60 mmHg), use low molecular heparin, weight of pre and post haemodialysis (Kg), blood pressure (BP) of pre and post haemodialysis (mmHg), heart rate of pre and post haemodialysis (BPM).

Laboratory examination data at baseline, 24 weeks, 48 weeks, 72 weeks and 96 weeks of follow-up, such as white blood cell (WBC), haemoglobin (Hb), platelet (Plt), ALT,

1
2
3
4 AST, total protein (TP), total bilirubin (TB), PH, HCO_3^- , K^+ , Na^+ , Cl^- , albumin (Alb),
5
6 total cholesterol (TC), Triglyceride (TG), LDL, HDL, Calcium, Phosphorus, iPTH,
7
8 ferritin, fasting blood glucose (Glu), C-reactive protein (CRP), β_2 -microglobulin (β
9
10 $_2$ -MG), B natriuretic peptides (BNP), thiamine, folic acid and homocysteine will be
11
12 collected. Transferrin saturation (TSAT) and dialysis adequacy (spKt/V) will be
13
14 calculated.

15
16 Cognitive function including MoCA^[15], MMSE^[16] and ADAS-Cog^[17,18] will be
17
18 assessed at baseline, 48 weeks and 96 weeks of follow-up.

19
20 Imageological examination including cranial functional magnetic resonance
21
22 imaging (fMRI) will be performed at baseline and 96 weeks of follow-up.

23 24 **Endpoints**

25 26 **Primary endpoint**

27
28 The primary endpoint is the comparison of ADAS-Cog score between the
29
30 treatment group and the control group at 96 weeks of follow-up.

31 32 **Secondary endpoints**

33
34 The secondary endpoint are listed below:

- 35
36 1. The comparison of serum thiamine, folate, and homocysteine levels between the
37
38 treatment and control groups at 96 weeks of follow-up.
- 39
40 2. The comparison of cranial functional magnetic resonance imaging between
41
42 treatment group and control group at 96 weeks of follow-up.
- 43
44 3. Survival comparison between treatment group and control group at 96 weeks of
45
46 follow-up.

47 48 **Safety endpoints**

49
50 Changes in laboratory safety indicators and incidence of adverse events between
51
52 the treatment and control groups during follow-up.

53 54 **Withdrawal and drop-out**

55
56 Shedding criteria

- 57
58 1. The researchers find serious safety problems
- 59
60 2. The effect is so poor that there was no need to continue the trial

Exit criteria

1. Subjects who meet the inclusion criteria and do not complete the study for any reason are considered to be withdrawal subjects, which include subjects' self-withdrawal and subjects' withdrawal determined by the investigator
 2. Severe adverse events occurred and the investigator considered it appropriate to withdraw from the study
 3. Major Trial Protocol Deviation Subjects are found to not meet the requirements of the trial protocol after randomization
 4. Serious other complications occurred during the clinical trial, and the investigators determined that it would not be beneficial to continue the study
 5. Unplanned pregnancy
 6. Lost follow-up, subjects do not return to the center, and contact with subjects failed
- If a subject is lost to follow-up, the investigator should make every effort to contact the subject and encourage the subject to continue to participate in the study as planned. If the subject withdraws their informed consent, the researcher should not evaluate the subject further and should not attempt to collect more data.

For subjects who withdraw from the trial early, the last interview should be arranged within 3 days after the withdrawal (the content of the interview should be determined by the investigator according to the actual situation of the subjects) to complete the efficacy and safety assessment.

Even if the subject is unable to return to the study center for visits, the investigator will complete all available data on the Case Report Form (CRF) and record the reason for early withdrawal. Whenever possible, the subject must return all drugs. The investigator will take inventory of the drug and complete the Drug Release and Recall Record Form.

Participant timeline

Please refer to figure 1 for details of the visit schedule and participant timeline.

Sample size and recruitment

Based on the previous single-center study, it was assumed that cognitive function (MoCA score) in the treatment group improved from 20 to 26, and set $\alpha=0.05$ and $1-\beta=0.9$, then at least 100 patients per group are required. In consideration of

1
2
3 control shedding or rejection rate within 15% during the test and subsequent analysis
4 requirements, 115 cases were planned to be enrolled in each group. The ratio of the
5 treatment group to the control group was 1:1, with 115 cases in the treatment group and
6 115 cases in the control group. This study will screen and enroll patients on
7 maintenance hemodialysis in three research centers.
8
9

10 11 12 **Randomisation**

13
14 The central randomization method will be adopted in this study and the principles
15 of placebo-controlled, double-blind randomized control will be followed. All eligible
16 subjects will be randomised in a ratio of 1:1 and divided into the treatment and control
17 arms.
18
19

20
21 Randomization sequence will be generated by an independent data manager using
22 SAS (version 9.3) and stored within sealed opaque envelopes. The investigator open an
23 envelope to obtain a number every time a patient is consented to enter the trial. Based
24 on this number, the patient is assigned the corresponding number of medication
25 (Treatment drugs or placebos).
26
27
28
29

30 31 **Blind and unblind**

32
33 This is a prospective, randomized, placebo-controlled, double-blind, multi-center
34 trial. This study will establish the program of blind setting and blind breaking. There
35 are both blind and non-blind drug administrators in this study. To ensure the
36 indistinguishable nature of the investigational drug, the blind drug administrator will
37 confirm the indistinguishable nature of the investigational drug and its matching
38 placebo in terms of appearance, taste, etc., before the investigational drug is distributed
39 and unblinded. The non-blind drug administrator creates a master random list of drugs
40 and creates a code break blind authorization number for emergency code break blind.
41 The non-blind drug administrator will securely store the master random list and the
42 code broken blind authorization number list until unblinding. The investigator will
43 develop and maintain a written emergency code blinding procedure to be followed in
44 response to an emergency.
45
46
47
48
49
50
51
52
53
54
55

56 57 **Selected data collection methods**

58 Cognitive function scores including MoCA, MMSE and ADAS-Cog will be
59 performed by board certified neurologists whenever possible. All cognitive function
60

1
2
3 scores will be performed before or during the interval of hemodialysis.
4

5 **Data statement**

6
7 The investigator must properly handle all the data obtained during the clinical trial,
8 and truthfully record all adverse events and serious adverse events during the clinical
9 trial, so as to ensure the rights and privacy of the subjects participating in the clinical
10 trial. Personal information of subjects will be collected, shared and maintained to
11 protect confidentiality during and after the study. Only the project investigator will have
12 access to the final trial data set.
13
14
15
16

17
18 A data monitoring committee (DMC) is composed of clinicians and
19 biostatisticians from Clinical Center for Investigation, Renji Hospital, School of
20 Medicine, Shanghai Jiao Tong University who are not involved in this study for the
21 purpose of ensuring the safety of subjects and the quality of study data.
22
23
24

25 **Statistical methods**

26 Data Set Category

- 27
28
29
30 1. Full Analysis Set(FAS): the case of using at least once drugs and main efficacy
31 indexes data after the drug administered.
32
33 2. Per Protocol Set(PPS): the good compliance case of meeting the main inclusion
34 and exclusion criteria without affecting the main curative effect of prohibiting
35 drugs during the trial.
36
37 3. Safety Set(SS): the case of using the investigational drug product at least once with
38 a safety evaluation.
39
40
41
42

43 Statistical analysis technique

44
45 It will be listed separately that the number of subjects selected and completed the
46 follow-up in the population and centers, identifying three analysis data sets (FAS, PPS,
47 SS) as specified above. The primary analysis only include patients with completed
48 primary outcomes. The comparisons among ADAS-Cog scores and other secondary
49 outcomes over time within subjects is conducted by using repeated measure ANOVA
50 or generalized estimating equations (GEE), and pairwise t-test with Bonferroni
51 adjustment is performed for multiple comparisons. On the other hand, for comparisons
52 between treatment and control group, simple one-way ANOVA, GEE or Wilcoxon
53 rank sum test is used. The chisquare method is used for statistical analysis of the
54
55
56
57
58
59
60

1
2
3 categorical data. For missing data in secondary efficacy outcomes, they are assumed to
4 be missing at random and multiple imputation was conducted. Kaplan-Meier survival
5 curve is used for survival analysis.
6
7

8
9 Variables of normal distribution are presented by means with SD while skewed
10 ones are reported as the median and the inter-quartile ranges. Counting data are
11 expressed as constituent ratios or percentages.
12
13

14 A $p < 0.05$ is considered statistically significant difference. Statistical analyses are
15 conducted with SPSS (Version 20.0, SPSS Inc., Chicago, IL, USA).
16
17

18 **Harms**

19
20 Safety endpoints relate directly to changes in laboratory safety indicators and
21 incidence of adverse events between the treatment and control groups during follow-
22 up. These endpoints will be listed according to treatment received with a breakdown.
23 Subjects will be followed up in detail, if any complications arise, appropriate treatment
24 will be provided in accordance with current routine medical procedures.
25
26
27
28
29

30 **Patient and Public Involvement statement**

31
32 The trial protocol was developed in part by nephrological and neurological
33 physicians with years of experience in treating MHD patients with CI. At the same time,
34 medical statisticians performed study design and sample size estimation. Patients and
35 the public have not yet been involved directly in the design, or conduct, or reporting,
36 or dissemination plans of this trial protocol.
37
38
39
40
41

42 **Ethics and dissemination**

43
44 This trial has been approved by Shanghai Jiao Tong University School of
45 Medicine, Renji Hospital Ethics Committee (KY2019-199). Other participating sub-
46 centers must also obtain ethics committee approval documents prior to the start of
47 clinical trials. The Good Clinical Practice(GCP)^[19] regulations shall be strictly followed
48 during the test implementation. This trial has been registered with the Chinese Clinical
49 Trial Registry (<http://www.chictr.org.cn/index.aspx>) at 22 Jan. 2020. Trial registration
50 number is ChiCTR2000029297. Amendments to the protocol will be reviewed by
51 Ethics Committees. Informed consent will be obtained before collecting any patient
52 data and patient information. After publication of study results, trial report will be
53
54
55
56
57
58
59
60

1
2
3
4 published in peer-reviewed journals and/or in national or international conferences. All
5 researchers involved in the design, discussion and writing of this study protocol, as the
6 authors.
7
8
9

10 11 **DISCUSSION**

12 Epidemiological study shows the number of dialysis patients is expected to rise to
13 2.162 million by 2030 in Asia^[20]. Meanwhile, cognitive impairment is a common
14 complications in ESRD patients^[1]. In pilot study, we enrolled 50 maintenance
15 hemodialysis patients with cognitive impairment, including the treatment group (n=25)
16 who received thiamine 90mg/day combined with folic acid 30mg/day and the control
17 group (n=25) who was the blank control group. After 2 years of follow-up, cognitive
18 function which was evaluated by MOCA score was significantly improved in the
19 treatment group. In addition, there was no statistically significant difference in safety
20 between the two groups.
21
22
23
24
25
26
27
28
29

30 Based on the results of this pilot study, we designed this prospective, randomized,
31 placebo-controlled, double-blind, multi-center trial. In this study, MHD patients with
32 CI from several large-scale hemodialysis centers in Shanghai will be enrolled in a
33 prospective, randomized, controlled, double-blind study. According to the sample size
34 of the pilot study, 230 subjects will be expected to be enrolled. The subjects will be
35 randomly divided into treatment group (n=115, thiamine 90mg/day combined with folic
36 acid 30mg/day) and control group (n=115, thiamine placebo 90mg/day combined with
37 folic acid placebo 30mg/day) and followed up for 96 weeks. Cognitive function scores,
38 serum levels of thiamine, folate and homocysteine, functional magnetic resonance
39 imaging of the brain, and safety measures will be monitored regularly.
40
41
42
43
44
45
46
47
48
49

50 This study hopes to verify added thiamine and folic acid reduces homocysteine
51 levels, so as to relieve the oxidative stress and improve cognitive function in patients
52 with MHD. To explore the benefits of supplementation with thiamine and folic acid in
53 the prognosis of MHD patients with CI. To evaluate the safety of thiamine and folic
54 acid in MHD patients. This study may provides evidence-based evidence for the clinical
55
56
57
58
59
60

1
2
3
4 treatment of this complication and ultimately lays a foundation for the organization and
5 implementation of higher level clinical research in this field.
6

7
8 This exploratory study would be conducted to evaluate the efficacy of thiamine
9 and folic acid supplement in the treatment of MHD patients complicated with CI, so as
10 to help clinically find an effective treatment for this complication and reach the leading
11 domestic and international level. It is helpful to promote the cross-collaboration and
12 common development of multi-centers and multi-disciplines, improve the ability and
13 level of the treatment of nervous system complications in MHD patients, and lay a
14 foundation for the organization and implementation of higher level clinical research in
15 this field.
16
17
18
19
20
21
22

23 Through this study, a breakthrough can be achieved in the treatment of MHD
24 patients complicated with CI, blocking the disease progression of MHD patients,
25 reducing the hospitalization rate, medical costs and mortality of MHD patients caused
26 by CI, improving the quality of life of MHD patients, thus improving the prognosis,
27 and having a good clinical application prospect.
28
29
30
31
32
33
34

35 **Acknowledgements**

36 We would like to thank East branch of Shanghai Sixth People's Hospital and
37 Shanghai Songjiang District Central Hospital for their contribution to the revision of
38 the study protocol as participating research centers.
39
40
41

42 **Author Contributors**

43 Renhua Lu and Leyi Gu were responsible for the design of the entire study,
44 including the drafting, revision and submission of clinical trial protocols. Weiming
45 Zhang, Yongping Guo, Xiujuan Zang, Huihua Pang, Shang Liu, Kewei Xie, Ping Li
46 and Xiaojun Zeng are responsible for the discussion and revision of clinical trial
47 protocol. Yan Zhou is responsible for designing the imaging tests. Ling Yu takes charge
48 of the design of cognitive function tests. Shuting Pan is responsible for the design of
49 statistical methods. Yifei Lu is in charge of the pharmacological mechanisms and
50 dosage selection of experimental drugs. All authors have read and approved the final
51 manuscript.
52
53
54
55
56
57
58
59
60

Funding

The clinical trial was supported by the 2017 Clinical research innovation training fund of Renji Hospital, School of Medicine, Shanghai Jiao Tong University under Grant PYIII-17-028; 2019 Special fund for clinical medical research of Chinese medical association under Grant 18020030782; 2019 Research seed fund training program of Renji Hospital, School of Medicine, Shanghai Jiao Tong University under Grant RJZZ19-004 and Clinical Research Plan of Shanghai Hospital Development Center under Grant SHDC2020CR4004.

Competing interests None declared.

Word count 4852.

Figure 1 An overview of this trial

References

1. Lu R, Kiernan MC, Murray A, Rosner MH, Ronco C. Kidney-brain crosstalk in the acute and chronic setting. *Nature Reviews Nephrology*. 2015;11(12):707-719.
2. Lu R, Xu C, Li Y, Yu L, Shao X, Xie K, et al. The Incidence Prognosis and Risk Factors of Cognitive Impairment in Maintenance Haemodialysis Patients. *Blood Purification*. 2019;47,:101-108.
3. Fujisaki K, Tsuruya K, Yamato M, Toyonaga J, Noguchi H, Nakano T, et al. Cerebral oxidative stress induces spatial working memory dysfunction in uraemic mice: neuroprotective effect of tempol. *Nephrol Dial Transplant*. 2014;29:529-538.
4. Alan S Hazell, Roger F Butterworth. Update of cell damage mechanisms in thiamine deficiency: focus on oxidative stress, excitotoxicity and inflammation. *Alcohol Alcohol*. 2009; 44: 141-147.
5. Calingasan NY, Chun WJ, Park LC et al. Oxidative stress is associated with region-specific neuronal death during thiamine deficiency. *J Neuropathol Exp Neurol*. 1999; 58: 946-958.
6. Langlais PJ, Anderson G, Guo SX et al. Increased cerebral free radical production during thiamine deficiency. *Metab Brain Dis*. 1997; 12: 137-143.
7. Stanger O. Physiology of folic acid in health and disease. *Curr Drug Metab*. 2002; 3: 211-223.
8. Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, et al. Folic Acid Therapy and Cardiovascular Disease in ESRD or Advanced Chronic Kidney Disease: A Meta-Analysis. *Clin J Am Soc Nephrol*. 2011;6:482-488.
9. Rex L Jamison, Pamela Hartigan, James S Kaufman, David S Goldfarb, Stuart R Warren, Peter D Guarino, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial, *JAMA*. 2007); 298(10):1163-1170.
10. Koh F, Charlton K, Walton K, McMahon AT. Role of Dietary Protein and Thiamine Intakes on Cognitive Function in Healthy Older People: A Systematic Review. *Nutrients*. 2015;7(4):2415-2439.
11. Ford AH, Almeida OP. Effect of Vitamin B Supplementation on Cognitive Function

1
2
3
4 in the Elderly: A Systematic Review and Meta-Analysis. *Drugs Aging*. 2019;36(5):419-
5 434.

6
7 12. Michael W Donnino, Jose Vega, Joseph Miller, Mark Walsh. Myths and
8 misconceptions of Wernicke's encephalopathy: what every emergency physician
9 should know. *Ann Emerg Med*. 2007;50:715-721.

10
11 13. Fuentebella J, Kerner JA. Refeeding syndrome. *Pediatr Clin North Am*. 2009;
12 56:1201-1210.

13
14 14. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K,
15 Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D.
16 SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials.
17 *BMJ*. 2013;346:e7586.

18
19 15. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment,
20 MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005;
21 53:695-699.

22
23 16. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for
24 grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975; 12:189-
25 198.

26
27 17. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. *Am*
28 *J Psychiatry*. 1984; 141(11):1356-1364.

29
30 18. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an
31 instrument for assessing treatment efficacy. *Psychopharmacol Bull*. 1983; 19(3):448-
32 450.

33
34 19. Good Clinical Practice (GCP) Instructions of National Medical Products
35 Administration of PR. China.
36 <https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200426162401243.html>. Accessed Apr
37 2020.

38
39 20. Thaminda Liyanage, Toshiharu Ninomiya, Vivekanand Jha, Bruce Neal, Halle
40 Marie Patrice, Ikechi Okpechi, et al. Worldwide access to treatment for end-stage
41 kidney disease: a systematic review. *Lancet*. 2015; 385(9981): 1975-1982.

Table 1 The visit schedule of this study

	screen	Randomization	Follow-up period			
Visiting period (weeks)		T0	T1	T2	T3	T4
	-4	0	24 ± 4	48 ± 4	72 ± 4	96 ± 4
Informed consent	×					
Inclusion and Exclusion Criteria	×					
Demographic data	×					
Medical history	×					
Information of haemodialysis	×		×	×	×	×
Laboratory examination	×		×	×	×	×
Cognitive function	×			×		×
Imageological examination	×					×
Drug Administration		×	×	×	×	×
Adverse Event	×	×	×	×	×	×




Figure 1 An overview of this trial

90x90mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	12
Protocol version	#3	Date and version identifier	2

1	Funding	#4	Sources and types of financial, material, and other support	14,15
2				
3				
4				
5	Roles and	#5a	Names, affiliations, and roles of protocol contributors	14
6	responsibilities:			
7	contributorship			
8				
9				
10				
11	Roles and	#5b	Name and contact information for the trial sponsor	n/a, no
12	responsibilities:			sponsor
13	sponsor contact			
14	information			
15				
16				
17				
18				
19	Roles and	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	n/a, no
20	responsibilities:			sponsor and
21	sponsor and funder			funder
22				
23				
24				
25				
26				
27				
28				
29				
30	Roles and	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	n/a, no
31	responsibilities:			committees
32	committees			
33				
34				
35				
36				
37				
38				
39				
40				
41	Introduction			
42				
43				
44	Background and	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3,4
45	rationale			
46				
47				
48				
49				
50				
51	Background and	#6b	Explanation for choice of comparators	4,5
52	rationale: choice of			
53	comparators			
54				
55				
56				
57	Objectives	#7	Specific objectives or hypotheses	4,5
58				
59				
60				

1	Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	5
2				
3				
4				
5				
6				
7				
8	Methods:			
9	Participants, interventions, and outcomes			
10				
11				
12				
13				
14				
15				
16	Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
17				
18				
19				
20				
21				
22				
23				
24	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5,6
25				
26				
27				
28				
29				
30				
31	Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6
32				
33				
34				
35				
36				
37				
38	Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	8,9
39				
40				
41				
42				
43				
44				
45	Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	6,7
46				
47				
48				
49				
50				
51	Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	8,9
52				
53				
54				
55				
56	Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	7,8
57				
58				
59				
60				

pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

1			
2			
3			
4			
5			
6			
7			
8			
9	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) 9
10			
11			
12			
13			
14			
15			
16			
17	Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations 9
18			
19			
20			
21			
22			
23			
24	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size 9
25			
26			
27			
28			
29	Methods:		
30	Assignment of		
31	interventions (for		
32	controlled trials)		
33			
34			
35			
36			
37	Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions 9,10
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49	Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 9,10
50			
51			
52			
53			
54			
55			
56	Allocation:	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 9,10
57			
58			
59			
60			

1	implementation	interventions	
2			
3	Blinding (masking)	#17a Who will be blinded after assignment to interventions	10
4		(eg, trial participants, care providers, outcome	
5		assessors, data analysts), and how	
6			
7			
8			
9	Blinding (masking):	#17b If blinded, circumstances under which unblinding is	10
10	emergency unblinding	permissible, and procedure for revealing a	
11		participant's allocated intervention during the trial	
12			
13			
14			
15	Methods: Data		
16	collection,		
17	management, and		
18	analysis		
19			
20			
21			
22			
23	Data collection plan	#18a Plans for assessment and collection of outcome,	6,7
24		baseline, and other trial data, including any related	
25		processes to promote data quality (eg, duplicate	
26		measurements, training of assessors) and a	
27		description of study instruments (eg, questionnaires,	
28		laboratory tests) along with their reliability and validity,	
29		if known. Reference to where data collection forms	
30		can be found, if not in the protocol	
31			
32			
33			
34			
35			
36			
37	Data collection plan:	#18b Plans to promote participant retention and complete	8,9
38	retention	follow-up, including list of any outcome data to be	
39		collected for participants who discontinue or deviate	
40		from intervention protocols	
41			
42			
43			
44	Data management	#19 Plans for data entry, coding, security, and storage,	10
45		including any related processes to promote data	
46		quality (eg, double data entry; range checks for data	
47		values). Reference to where details of data	
48		management procedures can be found, if not in the	
49		protocol	
50			
51			
52			
53			
54			
55	Statistics: outcomes	#20a Statistical methods for analysing primary and	11
56		secondary outcomes. Reference to where other details	
57		of the statistical analysis plan can be found, if not in	
58			
59			
60			

		the protocol	
1			
2			
3	Statistics: additional	#20b Methods for any additional analyses (eg, subgroup	11
4	analyses	and adjusted analyses)	
5			
6			
7			
8	Statistics: analysis	#20c Definition of analysis population relating to protocol	11
9	population and	non-adherence (eg, as randomised analysis), and any	
10	missing data	statistical methods to handle missing data (eg, multiple	
11		imputation)	
12			
13			
14			
15	Methods:		
16	Monitoring		
17			
18			
19			
20	Data monitoring:	#21a Composition of data monitoring committee (DMC);	10
21	formal committee	summary of its role and reporting structure; statement	
22		of whether it is independent from the sponsor and	
23		competing interests; and reference to where further	
24		details about its charter can be found, if not in the	
25		protocol. Alternatively, an explanation of why a DMC is	
26		not needed	
27			
28			
29			
30			
31			
32	Data monitoring:	#21b Description of any interim analyses and stopping	8,9
33	interim analysis	guidelines, including who will have access to these	
34		interim results and make the final decision to terminate	
35		the trial	
36			
37			
38			
39			
40	Harms	#22 Plans for collecting, assessing, reporting, and	11,12
41		managing solicited and spontaneously reported	
42		adverse events and other unintended effects of trial	
43		interventions or trial conduct	
44			
45			
46			
47			
48	Auditing	#23 Frequency and procedures for auditing trial conduct, if	n/a, no
49		any, and whether the process will be independent from	auditing
50		investigators and the sponsor	
51			
52			
53			
54	Ethics and		
55	dissemination		
56			
57			
58			
59			
60			

1	Research ethics	#24	Plans for seeking research ethics committee /	12
2	approval		institutional review board (REC / IRB) approval	
3				
4				
5	Protocol amendments	#25	Plans for communicating important protocol	12
6			modifications (eg, changes to eligibility criteria,	
7			outcomes, analyses) to relevant parties (eg,	
8			investigators, REC / IRBs, trial participants, trial	
9			registries, journals, regulators)	
10				
11				
12				
13				
14	Consent or assent	#26a	Who will obtain informed consent or assent from	12
15			potential trial participants or authorised surrogates,	
16			and how (see Item 32)	
17				
18				
19				
20				
21	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a, not
22	ancillary studies		participant data and biological specimens in ancillary	applicable
23			studies, if applicable	
24				
25				
26				
27	Confidentiality	#27	How personal information about potential and enrolled	10
28			participants will be collected, shared, and maintained	
29			in order to protect confidentiality before, during, and	
30			after the trial	
31				
32				
33				
34				
35	Declaration of	#28	Financial and other competing interests for principal	15
36	interests		investigators for the overall trial and each study site	
37				
38				
39	Data access	#29	Statement of who will have access to the final trial	10
40			dataset, and disclosure of contractual agreements that	
41			limit such access for investigators	
42				
43				
44				
45	Ancillary and post trial	#30	Provisions, if any, for ancillary and post-trial care, and	11
46	care		for compensation to those who suffer harm from trial	
47			participation	
48				
49				
50				
51	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate	12
52	trial results		trial results to participants, healthcare professionals,	
53			the public, and other relevant groups (eg, via	
54			publication, reporting in results databases, or other	
55			data sharing arrangements), including any publication	
56				
57				
58				
59				
60				

restrictions

1			
2			
3	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use
4	authorship		of professional writers
5			
6			
7			
8	Dissemination policy:	#31c	Plans, if any, for granting public access to the full
9	reproducible research		protocol, participant-level dataset, and statistical code
10			
11			

Appendices

12			
13			
14			
15			
16	Informed consent	#32	Model consent form and other related documentation
17	materials		given to participants and authorised surrogates
18			
19			
20	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage
21			of biological specimens for genetic or molecular
22			analysis in the current trial and for future use in
23			ancillary studies, if applicable
24			
25			
26			
27			

28 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative
 29 Commons Attribution License CC-BY-NC. This checklist can be completed online using
 30 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
 31 [Penelope.ai](#)
 32
 33